Ground state naïve pluripotent stem cells and CRISPR/Cas9 gene correction for β-thalassemia by Finotti, Alessia et al.
© Stem Cell Investigation. All rights reserved. Stem Cell Investig 2016;3:66sci.amegroups.com
Page 1 of 6
The β-thalassemias are a group of hereditary diseases 
caused by more than 300 mutations of the adult β-globin 
gene, leading to low or absent production of adult 
hemoglobin (HbA) (1-3). Together with sickle cell anemia 
(SCA), thalassemia syndromes are among the most 
impactful diseases in developing countries, in which the 
lack of genetic counselling and prenatal diagnosis have 
contributed to the maintenance of a very high frequency in 
the population. The management of β-thalassemia patients 
is mostly based on blood transfusion, chelation therapy and, 
alternatively, on bone marrow transplantation (2). Recently, 
novel therapeutic options have been explored, such as gene 
therapy (3) and fetal hemoglobin (HbF) induction (4). 
Despite the fact that these approaches are promising, they 
are at present still under deep experimental development and 
limited to a low number of clinical trials (2-4). With respect 
to gene therapy for β-thalassemia significant progresses are 
expected, also considering fundamental insights into globin 
switching and new technology developments which might 
have a strong impact on novel gene-therapy approaches (3). 
A robust information is however available regarding the 
management of β-thalassemia, i.e., that patients exhibiting 
high levels of endogenous HbF might exhibit a milder 
clinical status, as in the case of hereditary persistence of 
fetal hemoglobin (HPFH) (4). In this context, one of the 
most exciting strategies recently proposed for hereditary 
diseases, including β-thalassemia, is genome editing using 
a variety of strongly validated approaches. Among these 
strategies, the clustered regularly interspaced palindromic 
repeats (CRISPR)/Cas9 nuclease system (5-7), in which a 
single guide RNA (sgRNA) directs the Cas9 nuclease for 
site-specific cleavage, is considered the most efficient.
Molecular therapies based on genome editing can 
be grouped in gene correction strategies or genetic 
disruption (8). The first step in both cases is based on the 
induction of a double strand break (DSB) by an engineered 
nuclease, which is endogenously repaired by homology-
directed repair (HDR) or non-homologous end joining 
(NHEJ). Genetic correction strategies exploit the HDR 
pathway; the insertion of the corrected sequences (targeting 
specific gene mutations causing the molecular disease) is 
facilitated by the co-delivery of an extrachromosomal repair 
template in conjunction with the engineered nuclease, 
which improves the HDR frequency through the generation 
of DSB. By contrast, genetic disruption strategies are based 
on the NHEJ pathway following nuclease-induced DSB to 
produce local insertions/deletions (indels) (8). 
As outlined in Figure 1, the combination of HSPC 
(hematological stem precursor cells) and iPSCs (induced 
pluripotent stem cells) production with gene correction 
strategies appears one of the most exciting and potentially 
therapeutic approaches for genetic diseases, including 
hematological pathologies, such as β-thalassemia and 
SCA (3). The creation of iPSCs from somatic cells with 
the use of reprogramming factors (originally Oct3/4, 
Sox2, c-Myc, and Klf4) (9) represented a key issue in 
our understanding of developmental biology and in the 
design of novel therapeutic approaches, also considering 
that their use avoids the ethical concerns associated 
with human embryonal stem cells (hESCs) and creates a 
patient-specific, histocompatible substrate for cell therapy. 
With respect of the importance of HbF production in 
the management of β-thalassemia, and since human 
iPSCs retain embryonic and fetal characteristics of gene 
expression even upon erythroid differentiation in vitro, 
one of the expected possibility was that patient-derived 
iPSCs for β-thalassemia or SCA (10-13) were able to 
maintain high levels of γ-globin expression (3). However, 
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according to published in vivo findings after transplantation 
into immunodeficient mice, this very interesting possibility 
was not confirmed (14,15). Despite this apparent setback, 
iPSCs are a promising substrate for gene therapy, as they 
can be amplified in vitro indefinitely (where however they 
are still subject to the same mutation rates and potentially 
undesirable changes as any other cell type) and thus 
allow the clonal selection of guided events of therapeutic 
interest. Extensive use of iPSCs has been applied to the 
development of novel therapies for β-thalassemia and other 
hemoglobinopathies (3).
Induced pluripotent stem cells could be classified 
into two classes: primed iPSCs (12,13) and naïve iPSCs 
(16-20), both exhibiting therapeutic relevance. The naïve 
cells represent traits of mouse embryonic stem cells (mESC) 
derived from inner cell mass (ICM) or blastocyst from 
preimplantation embryo (18). Accordingly, naïve iPSCs 
exhibit molecular signatures of ground-state pluripotency 
with no tendency towards any lineage, retain an active 
X chromosome in female-derived iPSCs, are easier to 
be expanded and maintained, and differentiate along all 
the differentiation programs, due to the lack of lineage-
commitment (18). On the contrary, primed iPSCs resemble 
cells derived from murine post-implantation epiblasts, 
exhibit low efficiency in cellular expansion and presence 
of activated lineage-commitment, thus preventing full 
differentiation potential (8). 
In this context, a recent paper published by Yang 
et al. (21) on Stem Cell Translational Medicine clearly 
represents an important breakthrough. The relevance of 
the study of this group (from the Clinical and Translational 
Research Center of Shanghai, School of Life Sciences and 
Technology, Tongji University, China) is in the fact that 
they used the established 5i/L/FA system (18) to reprogram 
for the first time fibroblasts of a patient with β-thalassemia 
into transgene-free naïve iPSCs with molecular signatures 
of ground-state pluripotency. Using the CRISPR/Cas9 
genome editing system, it was shown that these naïve iPSCs 
exhibited significantly improved gene-correction efficiencies 
compared with the corresponding primed iPSCs.
Gene editing on iPSCs: general considerations
The relevant parameters to be considered in iPSC 
Figure 1 Therapeutic options for β-thalassemia based on gene therapy and gene editing. Modified from Finotti et al. (4). HSPC, 
hematological stem precursor cells; iPSC, induced pluripotent stem cells.
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gene editing are (I) the source of adult cells for iPSCs 
production; (II) the method for iPSCs production; (III) 
the genome editing system; (IV) the target genomic 
sequence(s) (8). These parameters impact with some 
features of the protocol, i.e., invasiveness of the sampling 
from β-thalassemia patients (point “I”); efficiency of 
iPSC production and growth ability (point “II”); off-
target effects, genotoxicity and gene correction efficiency 
(point “III”); type of strategy for recovery the biological 
activity of β-thalassemia erythroid cells by correcting 
the primary mutation, modify regulatory region, or both 
(point “IV”).
Production of naïve iPSCs and advantages of 
their use
In the procedure presented by Yang et al. (21) fibroblasts 
were used for naïve iPSC production. For transfection, 
episomal vectors were employed encoding Oct3, Sox2, 
Klf4, Myc and NANOG, i.e., factors that play a pivotal 
role in iPSCs generation, as originally reported by the 
pioneering work by Takahashi & Yamanaka (9). The 
episomal vectors allow a transgene-free strategy for the 
expression of iPSC inducing factors, minimizing the risk 
of genotoxicity associated with integration in the genome 
of target cells. After transfection, the cells were cultured 
in slightly modified conventional human embryonic stem 
cell medium (hESM) for 6 days. Then, the medium was 
replaced with human naïve medium (5i/L/FA medium) 
and cultured for 14–20 days. During this culture period 
dome-shaped colonies similar to mouse ESCs were clearly 
visible and were selected and expanded by single cell 
passaging. As far the source of adult stem cells, Yang et al. 
used adult fibroblast and urinary cells (21). Importantly, as 
published by several research teams, also other cell types 
can be reprogrammed into a ground state, such as adipose 
stem cells, peripheral blood cells and hepatocytes (16-19). 
Notably, the use of urinary cells can be considered as a non-
invasive technology (21).
The advantages of using naïve iPSCs are under debate 
and can be summarized as follows when comparison is made 
to primed iPSCs: high proliferation ability, efficient single-
cell cloning and recovery. These features facilitate mutant 
gene targeting and drug screening, allowing application 
of iPSCs in disease modeling and regenerative medicine. 
Moreover naïve iPSCs can efficiently produce cross-species 
chimeras, allowing the development of very appealing 
experimental model systems (21).
Gene editing: the choice of the strategy
The relative benefits of alternative gene editing systems is 
at present under debate and should be carefully monitored 
with respect to several parameters, of which the most 
important are efficiency and off-target effects. The genome 
editing system employed by Yang et al. (21) for genetic 
correction of the the naïve iPSCs was the CRISPR/Cas9 
strategy; however, other approaches can be considered, 
such as those based on zinc finger nucleases (ZFNs) (22) 
and TAL effector nucleases (TALENs) (23). Moreover, 
other Cas9-like systems have been described, including the 
CRISPR/Cpf1 nuclease platform, dimeric RNA-guided 
FokI nucleases, and use of Cas9’s derived from a variety of 
prokaryotic species (8). 
Gene editing: the choice of the genomic target
In the procedure developed by Yang et al. (21) the target 
genomic sequence was the β-41/42 mutation of the β-globin 
gene (HBB). This is characterized by a TCTT deletion 
between the 41st and 42nd amino acids of the HBB gene, 
causing a frame-shift leading to a β0-thalassemia phenotype. 
It is expected that this approach will be useful for any other 
β-thalassemia mutations, with the exception of large gene 
deletions in which globin gene addition (instead of globin 
gene correction) is required. 
While the CRISPR/CAS gene correction was directed 
to the β-thalassemia mutation, the described strategy 
might also consider targeting of other genomic regions 
involved in key processes, such as production of fetal 
hemoglobin and generation of a HPFH-like phenotype. It 
should be underlined that genome editing-based therapies 
include not only gene correction but also disruption of 
target gene regions. In the case of β-thalassemia this gene 
disruption targeting might include not only discrete regions 
of the β-globin gene cluster, but also direct or indirect 
transcriptional repressors of human γ-globin genes, such 
as BCL11A, MYB, HLF-1, EHMT1/EHMT2 and LRF/
ZBTB7A (see Figure 2). The description of these alternative 
targets in customizing gene editing has been recently 
reviewed by Canver and Orkin (8).
Combination therapy based on gene addition, 
gene editing and HbF inducers
As already pointed out, induction of endogenous HbF is 
one on the most widely applied therapeutic strategies for 
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β-thalassemia and SCA (4). While most of the recent studies 
in the field still focus on small-molecular-weight HbF 
inducers, more recently the innovative strategy of combining 
vector-derived β-globin with the induction of endogenous 
HbF has been investigated. The combined treatment induces 
an increase of both HbA (by gene addition) and HbF (by 
chemical HbF induction), with important therapeutic 
implications, given that gene augmentation in β-thalassemia 
major has been unable to reach physiological levels of 
β-like globin to date and might thus only lead to partial 
phenotypic correction (24). Since increased production of 
HbF is beneficial in β-thalassemia, the one-off application of 
gene therapy implemented with chronic application of HbF 
inducers appears to be a pertinent strategy to achieve clinical 
benefits not achievable with either strategy alone. When 
gene therapy was combined to HbF induction, the results 
obtained demonstrate that this combination strategy achieves 
high levels of functional hemoglobin in β-thalassemic cells 
and a concomitant sharp decrease of excess α-globin, with 
significant scope for further improvements for what is as yet 
a nascent field of research. This combined approach, at least 
in theory, also applies considering gene editing and HbF 
induction.
CRISPR/Cas9 and iPSCs technologies: from the 
laboratory to the clinic
Despite the promising developments of CRISPR-based 
methodologies, many challenges have to be overcome before 
the system can be applied therapeutically to human patients, 
enabling delivery technology being one of the key issues. 
With respect to consideration on clinical trial, ZFNs are the 
editing technologies considered in protocols fighting several 
pathologies. However, recent developments concern also 
the CRISPR/Cas9 approach, considered as the key genetic 
editing system in four clinical trials focusing on the use of 
PD-1 knockout engineered T cells for metastatic non-small 
cell lung cancer (clinicaltrials.gov NCT02793856) and renal 
cell carcinoma (clinicaltrials.gov NCT02867332), hormone 
refractory prostate cancer (clinicaltrials.gov NCT02867345) 
and invasive bladder cancer Stage IV (clinicaltrials.gov 
NCT02863913). In these clinical trials CRISPR/Cas9 is 
proposed to neutralize the PD-1 gene, which expresses a 
protein on T-cell surfaces that many cancers can turn off, 
thereby blocking T-cell antitumor attacks. Once expanded 
in the laboratory, the engineered cells will be returned to the 
patient, circulate and hopefully home in on the cancer site. 
Figure 2 Potential targets of the CRISPR/Cas9 gene editing for β-thalassemia. Genetic correction/repair strategies are based on specific 
and personalized modification of the β-globin gene cluster through (a1-a4) correction of the β-thalassemia mutations of the β-globin gene 
(reported examples: a1, β039; a2: β0-IVSI-1 and β+-IVSI-6; a3: β+-IVSI-110 and a4, β0-IVSII-1) or insertion of the HPFH-associated SNPs 
into the Gγ or Aγ promoters (b). Genetic disruption strategies involve targeted disruption of HbF associated sequences within the Aγ-δ 
intergenic region (c), coding sequence for repressors of the γ-globin gene transcription (some representative direct or indirect γ-globin gene 
repressors are shown in the upper part of the panel and include BCL11A, MYB, KLF1, LRF/ZBTB7A, or EHMT1/EHMT2) (d) or, if present, 
erythroid-specific enhancer regulating γ-globin gene repressors (e) (8). 
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On the other hand, the use of iPSCs in clinic is the 
object of a limited number of trials (more than 15 in 
clinicaltrials.gov), such as NCT00953693 (Patient Specific 
Induced Pluripotency Stem Cells), NCT02469207 
(Regenerative Cellular Therapies, Physiology, Pathology 
and Developmental Biology), NCT02162953 (Stem Cell 
Models of Best Disease and Other Retinal Degenerative 
Diseases) and NCT02056613 (Blood Collection From 
Healthy Volunteers and Patients for the Production of 
Clinical Grade Induced Pluripotent Stem Cell Products).
The CRISPR/Cas9 patent war
When it was clear that the CRISPR technology was easy 
to be adapted to mammalian cells for developing novel 
and very impactful therapeutic options, the interest in 
patenting both approach and biomedical applications 
increased dramatically. The interest on CRISPR/Cas9 
technology was the background for a spectacular patent 
war (25). Up to now the U.S. Patent and Trademark Office 
has granted more than 25 patents with claims concerning 
CRISPR and/or Cas9; among the more active institution 
and affiliated researchers is the Broad Institute, MIT, USA. 
Examples of granted patents are USP8871445 (CRISPR-
Cas component systems, methods and compositions for 
sequence manipulation), USP9102936 (Method of adaptor-
dimer subtraction using a CRISPR-CAS6 protein), 
USP8771945 (CRISPR-Cas systems and methods for 
altering expression of gene products) and USP8932814 
(CRISPR-Cas nickase systems, methods and compositions 
for sequence manipulation in eukaryotes). In addition to 
these granted patents, a huge number of patent applications 
have been filed. This patent war competition between 
biotech companies is aimed to get the first CRISPR system 
to the therapeutic market and, as expected, involves also 
academic institutions and research groups involved in the 
novel developments of specific applications of the CRISPR 
technology (25). At present the dispute concerning 
the CRISPR/Cas9 patenting continues and might be 
responsible for a significant delay in clinical applications.
Acknowledgements
The authors apologize for the several original studies and 
reviews that were not cited, due to space limitation.
In memory: This work is dedicated to our colleague and 
friend Dr. Chiara Gemmo.
Funding:  R Gambari is  supported by the UE FP7 
THALAMOSS Project (THALAssaemia MOdular 
Stratification System for personalized therapy of beta-
thalassemia;  grant no. 306201-FP7-Health-2012-
INNOVATION-1) and by Fondazione Cariparo (Cassa di 
Risparmio di Padova e Rovigo).
Footnote
Provenance: This is a Guest Editorial commissioned by 
Editor-in-Chief Zhizhuang Joe Zhao (Pathology Graduate 
Program, University of Oklahoma Health Sciences Center, 
Oklahoma City, USA).
Conflicts of Interest: The authors have no conflicts of interest 
to declare. 
Comment on: Yang Y, Zhang X, Yi L, et al. Naïve Induced 
Pluripotent Stem Cells Generated From β-Thalassemia 
Fibroblasts Allow Efficient Gene Correction With 
CRISPR/Cas9. Stem Cells Transl Med 2016;5:8-19.
References
1. Weatherall DJ. Phenotype-genotype relationships in 
monogenic disease: lessons from the thalassaemias. Nat 
Rev Genet 2001;2:245-55.
2. Finotti A, Borgatti M, Bianchi N, et al. Orphan Drugs 
and Potential Novel Approaches for Therapies of 
β-Thalassemia: Current Status and Future Expectations. 
Expert Opin Orphan Drugs 2016;4:299-315. 
3. Finotti A, Breda L, Lederer CW, et al. Recent trends 
in the gene therapy of β-thalassemia. J Blood Med 
2015;6:69-85.
4. Finotti A, Gambari R. Recent trends for novel options in 
experimental biological therapy of β-thalassemia. Expert 
Opin Biol Ther 2014;14:1443-54.
5. Traxler EA, Yao Y, Wang YD, et al. A genome-editing 
strategy to treat β-hemoglobinopathies that recapitulates a 
mutation associated with a benign genetic condition. Nat 
Med 2016;22:987-90.
6. Xu P, Tong Y, Liu XZ, et al. Both TALENs and CRISPR/
Cas9 directly target the HBB IVS2-654 (C &gt; T) 
mutation in β-thalassemia-derived iPSCs. Sci Rep 
2015;5:12065.
7. Niu X, He W, Song B, et al. Combining Single Strand 
Oligodeoxynucleotides and CRISPR/Cas9 to Correct 
Gene Mutations in β-Thalassemia-induced Pluripotent 
Stem Cells. J Biol Chem 2016;291:16576-85. 
8. Canver MC, Orkin SH. Customizing the genome 
Stem Cell Investigation, 2016
© Stem Cell Investigation. All rights reserved. Stem Cell Investig 2016;3:66sci.amegroups.com
Page 6 of 6
as therapy for the β-hemoglobinopathies. Blood 
2016;127:2536-45. 
9. Takahashi K, Yamanaka S. Induction of pluripotent stem 
cells from mouse embryonic and adult fibroblast cultures 
by defined factors. Cell 2006;126:663-76. 
10. Ye L, Chang JC, Lin C, et al. Induced pluripotent stem cells 
offer new approach to therapy in thalassemia and sickle cell 
anemia and option in prenatal diagnosis in genetic diseases. 
Proc Natl Acad Sci U S A 2009;106:9826-30. 
11. Breda L, Gambari R, Rivella S. Gene therapy in 
thalassemia and hemoglobinopathies. Mediterr J Hematol 
Infect Dis 2009;1:e2009008. 
12. Wang Y, Zheng CG, Jiang Y, et al. Genetic correction 
of β-thalassemia patient-specific iPS cells and its use in 
improving hemoglobin production in irradiated SCID 
mice. Cell Res 2012;22:637-48.
13. Fan Y, Luo Y, Chen X, et al. Generation of human 
β-thalassemia induced pluripotent stem cells from amniotic 
fluid cells using a single excisable lentiviral stem cell 
cassette. J Reprod Dev 2012;58:404-9. 
14. Ochi K, Takayama N, Hirose S, et al. Multicolor staining 
of globin subtypes reveals impaired globin switching 
during erythropoiesis in human pluripotent stem cells. 
Stem Cells Transl Med 2014;3:792-800.
15. Dias J, Gumenyuk M, Kang H, et al. Generation of red 
blood cells from human induced pluripotent stem cells. 
Stem Cells Dev 2011;20:1639-47.
16. Hanna JH. The STATs on naive iPSC reprogramming. 
Cell Stem Cell 2010;7:274-6. 
17. Nishishita N, Shikamura M, Takenaka C, et al. Generation 
of virus-free induced pluripotent stem cell clones on a 
synthetic matrix via a single cell subcloning in the naïve 
state. PLoS One 2012;7:e38389. 
18. Theunissen TW, Powell BE, Wang H, et al. Systematic 
identification of culture conditions for induction and 
maintenance of naive human pluripotency. Cell Stem Cell 
2014;15:471-87.
19. Sanal MG. A highly efficient method for generation of 
therapeutic quality human pluripotent stem cells by using 
naive induced pluripotent stem cells nucleus for nuclear 
transfer. SAGE Open Med 2014;2:2050312114550375. 
20. Ou Z, Niu X, He W, et al. The Combination of CRISPR/
Cas9 and iPSC Technologies in the Gene Therapy of 
Human β-thalassemia in Mice. Sci Rep 2016;6:32463. 
21. Yang Y, Zhang X, Yi L, et al. Naïve Induced Pluripotent 
Stem Cells Generated From β-Thalassemia Fibroblasts 
Allow Efficient Gene Correction With CRISPR/Cas9. 
Stem Cells Transl Med 2016;5:8-19. 
22. Ma N, Shan Y, Liao B, et al. Factor-induced 
Reprogramming and Zinc Finger Nuclease-aided 
Gene Targeting Cause Different Genome Instability in 
β-Thalassemia Induced Pluripotent Stem Cells (iPSCs). J 
Biol Chem 2015;290:12079-89. 
23. Ma N, Liao B, Zhang H, et al. Transcription activator-like 
effector nuclease (TALEN)-mediated gene correction in 
integration-free β-thalassemia induced pluripotent stem 
cells. J Biol Chem 2013;288:34671-9. 
24. Zuccato C, Breda L, Salvatori F, et al. A combined approach 
for β-thalassemia based on gene therapy-mediated adult 
hemoglobin (HbA) production and fetal hemoglobin (HbF) 
induction. Ann Hematol 2012;91:1201-13. 
25. Sherkow JS. Law, history and lessons in the CRISPR 
patent conflict. Nat Biotechnol 2015;33:256-7.
doi: 10.21037/sci.2016.09.21
Cite this article as: Finotti A, Borgatti M, Gambari R. Ground 
state naïve pluripotent stem cells and CRISPR/Cas9 gene 
correction for β-thalassemia. Stem Cell Investig 2016;3:66.
